SG10201509145XA - Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers - Google Patents
Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancersInfo
- Publication number
- SG10201509145XA SG10201509145XA SG10201509145XA SG10201509145XA SG10201509145XA SG 10201509145X A SG10201509145X A SG 10201509145XA SG 10201509145X A SG10201509145X A SG 10201509145XA SG 10201509145X A SG10201509145X A SG 10201509145XA SG 10201509145X A SG10201509145X A SG 10201509145XA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor alpha
- folate receptor
- diagnostic
- prognostic marker
- expressing cancers
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41049710P | 2010-11-05 | 2010-11-05 | |
| US201161508444P | 2011-07-15 | 2011-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201509145XA true SG10201509145XA (en) | 2015-12-30 |
Family
ID=45003076
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201701933XA SG10201701933XA (en) | 2010-11-05 | 2011-11-04 | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| SG10201509145XA SG10201509145XA (en) | 2010-11-05 | 2011-11-04 | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| SG2013030424A SG189957A1 (en) | 2010-11-05 | 2011-11-04 | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201701933XA SG10201701933XA (en) | 2010-11-05 | 2011-11-04 | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013030424A SG189957A1 (en) | 2010-11-05 | 2011-11-04 | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120207771A1 (de) |
| EP (2) | EP3130605B1 (de) |
| JP (2) | JP6224456B2 (de) |
| KR (2) | KR102057438B1 (de) |
| CN (2) | CN108562744A (de) |
| AU (3) | AU2011323124C1 (de) |
| BR (1) | BR112013011072B1 (de) |
| CA (1) | CA2816991C (de) |
| ES (2) | ES2780192T3 (de) |
| IL (2) | IL225871B (de) |
| MX (2) | MX368394B (de) |
| RU (2) | RU2764592C2 (de) |
| SG (3) | SG10201701933XA (de) |
| WO (1) | WO2012061759A2 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2172487A1 (de) * | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antikörper mit Immuneffektoraktivität, die in Folatrezeptor alpha-positive Zellen internalisiert werden |
| UA123257C2 (uk) | 2010-02-24 | 2021-03-10 | Іммуноджен, Інк. | Виділений поліпептид, що кодує антитіло до рецептора фолієвої кислоти 1 |
| US20120189620A1 (en) * | 2011-01-21 | 2012-07-26 | Emory University | Methods for treating non-functioning pituitary adenoma |
| EP2680839A1 (de) * | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Gleichzeitige verabreichung von eribulin und farletuzumab zur behandlung von brustkrebs |
| PT2694106T (pt) | 2011-04-01 | 2018-03-05 | Immunogen Inc | Métodos para aumentar eficácia de terapia de cancro de folr1 |
| PL2731972T3 (pl) * | 2011-07-15 | 2018-06-29 | Eisai R&D Management Co., Ltd. | Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania |
| BR112014028306A2 (pt) | 2012-05-15 | 2018-04-17 | Morphotek, Inc. | métodos para tratamento de câncer gástrico. |
| NZ726258A (en) * | 2012-08-31 | 2019-07-26 | Immunogen Inc | Antibodies and uses thereof to detect folate receptor 1 |
| JP6383787B2 (ja) * | 2013-06-20 | 2018-08-29 | モルフォテック， インコーポレイテッド | 卵巣癌の治療方法 |
| SG10201907501QA (en) | 2013-08-30 | 2019-10-30 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
| WO2015054400A2 (en) * | 2013-10-08 | 2015-04-16 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
| SI3221357T1 (sl) | 2014-11-20 | 2020-09-30 | F. Hoffmann-La Roche Ag | Pogoste lahke verige in načini uporabe |
| EP3789402B1 (de) | 2014-11-20 | 2022-07-13 | F. Hoffmann-La Roche AG | Kombinationstherapie von t-zell-aktivierenden bispezifischen antigenbindenden molekülen und pd-1-achsen-bindenden antagonisten |
| JP2018516244A (ja) | 2015-04-17 | 2018-06-21 | モーフォテック， インコーポレイテッド | 肺がんを処置するための方法 |
| KR102700777B1 (ko) | 2015-09-17 | 2024-08-29 | 이뮤노젠 아이엔씨 | 항-folr1 면역접합체를 포함하는 치료제 조합 |
| US11344628B2 (en) | 2016-08-12 | 2022-05-31 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| US10822410B2 (en) | 2016-11-23 | 2020-11-03 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| CN107446021B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽5及其应用 |
| CN107353325B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽1及其应用 |
| CN107446020B (zh) * | 2017-07-28 | 2019-10-01 | 中国药科大学 | 叶酸受体α特异性结合肽2及其应用 |
| RU2759410C2 (ru) * | 2017-09-05 | 2021-11-12 | Иммьюноджен, Инк. | Способы обнаружения фолатного рецептора 1 в образце пациента |
| EP3749316A4 (de) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | Alpha-polyglutamatiertes pralatrexat und verwendungen davon |
| US12076402B2 (en) | 2018-02-07 | 2024-09-03 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| JP7491572B2 (ja) | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
| EP3752156A4 (de) | 2018-02-14 | 2021-10-27 | L.E.A.F Holdings Group LLC | Gamma-polyglutamiertse pralatrexat und verwendungen davon |
| US11771700B2 (en) | 2018-02-14 | 2023-10-03 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| EP3755335A4 (de) | 2018-02-14 | 2022-06-22 | L.E.A.F Holdings Group LLC | Gamma-polyglutamierte tetrahydrofolate und deren verwendungen |
| SG11202007494TA (en) * | 2018-03-13 | 2020-09-29 | Phanes Therapeutics Inc | Anti-folate receptor 1 antibodies and uses thereof |
| JP2022523564A (ja) | 2019-03-04 | 2022-04-25 | アイオーカレンツ， インコーポレイテッド | 機械学習を使用するデータ圧縮および通信 |
| JP2022530524A (ja) | 2019-04-29 | 2022-06-29 | イミュノジェン， インコーポレイテッド | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート |
| US20240226312A1 (en) * | 2021-06-04 | 2024-07-11 | Immunogen, Inc. | Treatment of cancer in patients with soluble fr-alpha |
| CN117700557B (zh) * | 2024-02-05 | 2024-04-30 | 卡秋(江苏)生物科技有限公司 | 一种特异性结合叶酸受体α的抗体或抗原结合片段 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| EP2192131A1 (de) | 1992-08-21 | 2010-06-02 | Vrije Universiteit Brussel | Immunglobuline ohne Leichtkette |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| ATE267877T1 (de) | 1993-01-07 | 2004-06-15 | Sequenom Inc | Dns - sequenzierung durch massenspektronomie |
| JPH08507926A (ja) | 1993-03-19 | 1996-08-27 | シーケノム・インコーポレーテツド | エキソヌクレアーゼ分解を介した質量分析法によるｄｎａ配列決定 |
| WO1998031700A1 (en) | 1997-01-21 | 1998-07-23 | The General Hospital Corporation | Selection of proteins using rna-protein fusions |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6933108B2 (en) * | 1999-12-09 | 2005-08-23 | The Regents Of The University Of California | Methods and compositions for use in the treatment of filovirus mediated disease conditions |
| JP2004512540A (ja) * | 2000-11-01 | 2004-04-22 | マウント・サイナイ・ホスピタル | 卵巣癌の検出 |
| US20100120078A1 (en) * | 2001-08-16 | 2010-05-13 | Tony Baker | Urine Stabilization System |
| CA2784450C (en) * | 2001-11-13 | 2016-09-13 | Id Biomedical Corporation | Polypeptides of pseudomonas aeruginosa |
| AU2003253589A1 (en) * | 2002-03-26 | 2003-11-10 | Centocor, Inc. | Epitope mapping using nuclear magnetic resonance |
| WO2004082463A2 (en) * | 2003-03-17 | 2004-09-30 | Medical College Of Ohio | Folate receptor gene modulation for cancer diagnosis and therapy |
| EP1626991A2 (de) | 2003-05-23 | 2006-02-22 | Morphotek, Inc. | Anti-alpha-folsäure-rezeptor-tetramer antikörper |
| WO2005047534A2 (en) * | 2003-10-28 | 2005-05-26 | Bayer Healthcare Ag | Methods and compositions for the response prediction of malig-nant neoplasia to treatment |
| EP1716179A2 (de) | 2004-02-12 | 2006-11-02 | Morphotek, Inc. | Monoklonaler antikörper spezifisch für den folatrezeptor alpha |
| CA2602585A1 (en) * | 2005-03-30 | 2006-10-05 | Purdue Research Foundation | Method for cancer prognosis using cellular folate vitamin receptor quantification |
| EP2172487A1 (de) * | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antikörper mit Immuneffektoraktivität, die in Folatrezeptor alpha-positive Zellen internalisiert werden |
| EP1996940B1 (de) * | 2006-02-09 | 2011-12-21 | University of South Florida | Nachweis von krebs anhand von erhöhten bcl-2-konzentrationen |
| US8486412B2 (en) * | 2006-06-01 | 2013-07-16 | Mayo Foundation For Medical Education And Research | Immunity to folate receptors |
| EP1900752A1 (de) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Humane anti-Folatrezeptor-alpha Antikörper und -fragmente für die Radioimmuntherapie von Eierstockkrebs |
| US7754698B2 (en) | 2007-01-09 | 2010-07-13 | Isis Pharmaceuticals, Inc. | Modulation of FR-alpha expression |
| US20100216718A1 (en) * | 2007-10-19 | 2010-08-26 | Cell Signaling Technology, Inc. | Cancer Classification and Methods of Use |
| WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
| US20110177525A1 (en) * | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
| AU2011291599B2 (en) * | 2010-08-18 | 2015-09-10 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for disease |
-
2011
- 2011-11-04 SG SG10201701933XA patent/SG10201701933XA/en unknown
- 2011-11-04 AU AU2011323124A patent/AU2011323124C1/en active Active
- 2011-11-04 ES ES16186634T patent/ES2780192T3/es active Active
- 2011-11-04 ES ES11785862.1T patent/ES2627061T3/es active Active
- 2011-11-04 BR BR112013011072-4A patent/BR112013011072B1/pt active IP Right Grant
- 2011-11-04 SG SG10201509145XA patent/SG10201509145XA/en unknown
- 2011-11-04 JP JP2013537884A patent/JP6224456B2/ja active Active
- 2011-11-04 CA CA2816991A patent/CA2816991C/en active Active
- 2011-11-04 KR KR1020187036506A patent/KR102057438B1/ko active IP Right Grant
- 2011-11-04 MX MX2016011546A patent/MX368394B/es unknown
- 2011-11-04 EP EP16186634.8A patent/EP3130605B1/de active Active
- 2011-11-04 EP EP11785862.1A patent/EP2635304B1/de active Active
- 2011-11-04 MX MX2013005067A patent/MX343607B/es active IP Right Grant
- 2011-11-04 RU RU2017129266A patent/RU2764592C2/ru active
- 2011-11-04 SG SG2013030424A patent/SG189957A1/en unknown
- 2011-11-04 RU RU2013125772A patent/RU2630608C2/ru active
- 2011-11-04 US US13/289,892 patent/US20120207771A1/en not_active Abandoned
- 2011-11-04 CN CN201710961050.XA patent/CN108562744A/zh active Pending
- 2011-11-04 KR KR1020137014442A patent/KR101931936B1/ko active IP Right Grant
- 2011-11-04 CN CN201180064293.4A patent/CN103687618A/zh active Pending
- 2011-11-04 WO PCT/US2011/059411 patent/WO2012061759A2/en active Application Filing
-
2013
- 2013-04-21 IL IL225871A patent/IL225871B/en active IP Right Grant
-
2016
- 2016-05-25 AU AU2016203408A patent/AU2016203408A1/en not_active Abandoned
-
2017
- 2017-10-04 JP JP2017194027A patent/JP6554152B2/ja active Active
-
2018
- 2018-03-12 AU AU2018201760A patent/AU2018201760B2/en active Active
- 2018-07-13 IL IL260590A patent/IL260590B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260590B (en) | Receptor alpha emitting as a diagnostic and prognostic marker for cancer expressing receptor alpha emitting | |
| HK1135940A1 (en) | Self-powered coordinate probe | |
| EP2585833A4 (de) | Verfahren zur krebserkennung | |
| EP2630917A4 (de) | Brustvermessungsvorrichtung | |
| EP2569446A4 (de) | Diagnostische marker für neuropsychiatrische erkrankungen | |
| GB201414085D0 (en) | Breast cancer diagnosis and indication marker | |
| EP2636040A4 (de) | Rückkopie-operationen | |
| EP2748608A4 (de) | Lungenkrebstests | |
| EP2634544A4 (de) | Kollektive rutsche für eine mehrkopfwaage | |
| GB201012590D0 (en) | Methods for diagnosing cancer | |
| EP2524702A4 (de) | Diagnosemittel für krebs | |
| EP2495561A4 (de) | Marker zur bestimmung der empfindlichkeit für ein antikrebsmittel | |
| ZA201200888B (en) | New tumor marker | |
| HK1176977A1 (en) | Marker for gastric cancer and method for detecting gastric cancer | |
| EP2486154A4 (de) | Diagnostische und prognostische marker für krebs | |
| EP2531616A4 (de) | Diagnose- und prognose-assay für brustkrebs | |
| GB201414102D0 (en) | Colorectal cancer diagnosis and indication marker | |
| GB2477687B (en) | X-ray marker | |
| EP2735571A4 (de) | Antikörper für darmkrebsmarker | |
| PT2386459E (pt) | Sistema de localização de comboios | |
| GB0905964D0 (en) | Marker | |
| TWI563256B (en) | Marker for colon cancer and method for detecting colon cancer | |
| GB2484553B (en) | A tunnelling device | |
| GB201016212D0 (en) | Marker device | |
| GB201001946D0 (en) | Cancer prognostic assay |